Haloperidol Decanoate Injection

Description

Product Description: Haloperidol Decanoate Injection is a sterile, long-acting injectable formulation of haloperidol decanoate, a potent antipsychotic medication. It is indicated for the treatment of various psychiatric disorders, including schizophrenia and other psychotic disorders. Formulated for intramuscular administration, Haloperidol Decanoate Injection provides sustained therapeutic effects, reducing the frequency of dosing and enhancing patient compliance.

Indications and Usage: Haloperidol Decanoate Injection is indicated for the management of schizophrenia and other psychotic disorders in patients who require long-term antipsychotic therapy. It is particularly beneficial for patients who have demonstrated a clinical response to oral haloperidol but require maintenance treatment with a longer duration of action.

Dosage and Administration: The dosage of Haloperidol Decanoate Injection varies depending on the patient's clinical condition, previous response to haloperidol, and individualized treatment goals. It is administered via deep intramuscular injection into the gluteal muscle using a suitable needle and syringe. The recommended initial dose and dosing interval should be determined by the healthcare provider based on the patient's response to oral haloperidol and other factors.

Dosage Forms and Strengths: Haloperidol Decanoate Injection is available as a sterile solution in vials containing haloperidol decanoate in specific concentrations. Each mL of the injection contains a defined amount of haloperidol decanoate, allowing for accurate dosing and therapeutic efficacy.

Contraindications: This product is contraindicated in patients with a known hypersensitivity to haloperidol or any of the excipients. It should not be used in patients with severe central nervous system depression, comatose states, or in those with known or suspected subcortical brain damage. Additionally, caution should be exercised in patients with a history of QT prolongation or arrhythmias.

Warnings and Precautions: Healthcare providers should monitor patients receiving Haloperidol Decanoate Injection for signs of neuroleptic malignant syndrome (NMS), tardive dyskinesia, and extrapyramidal symptoms (EPS). Patients should be monitored regularly for changes in mental status, cardiovascular function, and metabolic parameters during treatment. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

Adverse Reactions/Side Effects: Common adverse reactions associated with Haloperidol Decanoate Injection include drowsiness, dizziness, extrapyramidal symptoms, and akathisia. Other potential side effects include weight gain, constipation, and anticholinergic effects. Patients should be monitored closely for adverse reactions, and therapy should be adjusted as necessary to minimize discomfort and improve tolerability.

Drug Interactions: Haloperidol Decanoate Injection may interact with other medications, including anticholinergic drugs, CNS depressants, and medications that prolong the QT interval. Healthcare providers should review the patient's medication profile carefully to identify potential drug interactions and adjust dosage as necessary to minimize risks.

Use In Specific Populations Description: Safety and efficacy of Haloperidol Decanoate Injection in pediatric patients, elderly patients, and pregnant or nursing women have not been established conclusively. Healthcare providers should assess the potential risks and benefits before prescribing this medication in these populations.

How Supplied/Storage and Handling: Haloperidol Decanoate Injection is supplied as a sterile solution in vials for intramuscular administration. It should be stored at controlled room temperature (20°C to 25°C) away from light and moisture. Care should be taken to ensure proper storage and handling to maintain the integrity of the product. Unused portions should be discarded according to standard procedures for biohazardous waste.